

About AIMP

When your child is diagnosed with a rare disease it can be very tough, especially if no informative resources are available.

Our patient-led organization was started in 2017 by parents of children with macrodactyly and now provides support to persons with all the PIK3CA related conditions and their families.

We have a **Scientific Committee** and co-operate with various clinicians, researchers and clinical centers with expertise in our conditions.

Some of our achievements

- Dec 2017
- → 1st Italian meeting on macrodactyly (families and doctors)
- Nov 2018
- → macrodactyly recognized as a rare disease and exemption from out-ofpocket costs for diagnosis and care
- Oct 2020
- → Online webinar on PIK3CA related conditions (families and doctors)

Our vision

Our vision is a world where...

- the natural history of macrodactyly and PIK3CA related conditions is well characterized
- shared recommendations for diagnosis and management exist
- persons with PIK3CA related conditions can have equal access to diagnosis, clinical, medical and social care and to opportunities for selfrealization.

We are committed to...

- Mutual aid
- Support and information for families
- Support for research
- Collaboration with clinical centers and other patient groups

- Developing diagnosis and management recommendations specific for Italy
 Finalizing an agreement with a Telethon Biobank
 Expanding the PROS network in Italy
 Developing additional educational materials for persons with PIK3CA related conditions and their families their families
- * Creating a disease registry

About macrodactyly

Macrodactyly is a condition where a baby's toes or fingers and/or the entire hand/or foot are enlarged due to overgrowth of bone, soft tissue and nerves. It can severely impact a child's ability to perform normal activities. Macrodactyly is not inherited and is often a PIK3CA related condition. Surgery is currently the only treatment option available and is aimed at restoring function. Medical treatment and access to clinical trials is generally not available due to an unfavorable risk/benefit balance.











